Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Hematologic Profiles in the Phase 3 APEX Trial.

Sagar Lonial, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3474.

https://doi.org/10.1182/blood.V106.11.3474.3474

Published: 2005

Journal Articles

Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years.

Blood (2005) 106 (11): 3414.

https://doi.org/10.1182/blood.V106.11.3414.3414

Published: 2005

Journal Articles

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

J.F. San Miguel, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 366.

https://doi.org/10.1182/blood.V106.11.366.366

Published: 2005

Journal Articles

Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma.

Blood (2005) 106 (11): 46.

https://doi.org/10.1182/blood.V106.11.46.46

Published: 2005

Journal Articles

Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma.

B. Bruno, M. Ladetto, M. Astolfi, L. Veneziano, L. Cimolin, E. Galletto, G. Pagliano, M. Rotta, N. Mordini, L. Giaccone, P. Omedè, S. Battaglio, R. Storb, M. Boccadoro

Blood (2004) 104 (11): 5128.

https://doi.org/10.1182/blood.V104.11.5128.5128

Published: 2004

Journal Articles

Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry.

Blood (2004) 104 (11): 1432.

https://doi.org/10.1182/blood.V104.11.1432.1432

Published: 2004

Journal Articles

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2004) 104 (11): 1479.

https://doi.org/10.1182/blood.V104.11.1479.1479

Published: 2004

Journal Articles

Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after [letter]

C Pellat-Deceunynk, M Amiot, R Bataille, I Van Riet, B Van Camp, P Omede, M Boccadoro

Blood (1995) 86 (10): 4001–4002.

https://doi.org/10.1182/blood.V86.10.4001.bloodjournal86104001

Published: 1995

Journal Articles

Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients

M Massaia, P Borrione, C Attisano, P Barral, E Beggiato, L Montacchini, A Bianchi, M Boccadoro, A Pileri

Blood (1995) 85 (12): 3679–3687.

https://doi.org/10.1182/blood.V85.12.3679.bloodjournal85123679

Published: 1995

Journal Articles

High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting

P Corradini, C Voena, M Astolfi, M Ladetto, C Tarella, M Boccadoro, A Pileri

Blood (1995) 85 (6): 1596–1602.

https://doi.org/10.1182/blood.V85.6.1596.bloodjournal8561596

Published: 1995

Journal Articles

Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype

U Dianzani, P Omede, F Marmont, D DiFranco, A Fusaro, M Bragardo, V Redoglia, F Giaretta, L Mairone, M Boccadoro

Blood (1994) 83 (8): 2198–2205.

https://doi.org/10.1182/blood.V83.8.2198.2198

Published: 1994

Journal Articles

Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? [letter; comment]

M Boccadoro, G Gallone, R Frieri, A Pileri, R Bataille, B Klein

Blood (1993) 82 (11): 3507–3508.

https://doi.org/10.1182/blood.V82.11.3507.3507

Published: 1993

Journal Articles

Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells

M Massaia, C Attisano, S Peola, L Montacchini, P Omede, P Corradini, D Ferrero, M Boccadoro, A Bianchi, A Pileri

Blood (1993) 82 (6): 1787–1797.

https://doi.org/10.1182/blood.V82.6.1787.1787

Published: 1993

Journal Articles

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias

P Corradini, M Ladetto, C Voena, A Palumbo, G Inghirami, DM Knowles, M Boccadoro, A Pileri

Blood (1993) 81 (10): 2708–2713.

https://doi.org/10.1182/blood.V81.10.2708.2708

Published: 1993

Journal Articles

C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system

R Bataille, M Boccadoro, B Klein, B Durie, A Pileri

Blood (1992) 80 (3): 733–737.

https://doi.org/10.1182/blood.V80.3.733.733

Published: 1992

Journal Articles

Analysis of immunoglobulin heavy chain gene rearrangement using the polymerase chain reaction [letter; comment]

P Corradini, M Boccadoro, A Pileri

Blood (1992) 79 (1): 291–292.

https://doi.org/10.1182/blood.V79.1.291.291

Published: 1992

Journal Articles

Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival

P Omede, M Boccadoro, G Gallone, R Frieri, S Battaglio, V Redoglia, A Pileri

Blood (1990) 76 (7): 1375–1379.

https://doi.org/10.1182/blood.V76.7.1375.1375

Published: 1990

Journal Articles

The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation

L Pegoraro, F Malavasi, G Bellone, M Massaia, M Boccadoro, G Saglio, A Guerrasio, G Benetton, L Lombardi, R Coda

Blood (1989) 73 (4): 1020–1027.

https://doi.org/10.1182/blood.V73.4.1020.1020

Published: 1989

Journal Articles

Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status

U Dianzani, A Pileri, M Boccadoro, A Palumbo, P Pioppo, A Bianchi, A Camponi, G Fossati, S Battaglio, M Massaia

Blood (1988) 72 (3): 1064–1068.

https://doi.org/10.1182/blood.V72.3.1064.1064

Published: 1988

NARROW

Hematologic Profiles in the Phase 3 APEX Trial.

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years.

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma.

Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma.

Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry.

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after [letter]

Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients

High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting

Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype

Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? [letter; comment]

Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias

C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system

Analysis of immunoglobulin heavy chain gene rearrangement using the polymerase chain reaction [letter; comment]

Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival

The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation

Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only